MARKET WIRECNBC • 2h ago
Here are 3 big things we're watching in the stock market in the week aheadThe market could use a few victories in the days ahead, which will be filled with more earnings, an election, and jobs data.
Why MBIO Stock surged +9.00% Today — RQD Quant Desk Flash
$0.39 +9.00% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot)
EXT / AFTER-HRS: $0.40
Mustang Bio Inc. (MBIO) carries a Roarable Rating of D- (Sell) with 43/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
ROARABLE D- • SELL / AVOID
Cap $3.0M
INTERACTIVE SCENARIO DECK:
EXT / AFTER-HRS: $0.40 (+1.43%)🧬 Disciplined Float (+0.72% YoY Shares)⚙️ Cash Engine: 4/20 (E) • 0% FCF Margin
Verify 90D Bucket Audit →📊 Historical Track Record Warning: Scores below 50 (43/100 · D-) historically underperformed SPY in 71% of rolling 90-day windows (-6.7% avg 90D alpha vs SPY • 29.0% hit rate).
Audit Bucket Track Record →RQD QUANT TACHOMETERSELL / AVOID • D-
3-of-3 JEV AI Jury Bearish Warning
Cash
SEC
Whale
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
5-PILLAR SNOWFLAKE RADARRw D- · Rk D
Each axis scored 0–20
12M PRICE TARGET CONE-7.7% Base Target
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for MBIO)Realized 20D OHLCV Swing Band: ±12.5%
Deterministic 5-Pillar Attribution (43/100 Composite)
🔍 WHY MBIO SCORES 43/100 (D-) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: Whale & Options Positioning+14/20 pts (33% of score)
20D Institutional Volume Accumulation (±12.5% realized swing band)
▲ #2 Bullish Driver: SEC 10-K Forensic Risk+10/20 pts (23% of score)
Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 2/9
▼ #1 Drag / Risk Factor: Cash Engine Quality4/20 pts (-16 pt drag)
Capital intensity & 0% operating margin leave 16 pts on the table
📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)Grade C-$0.40-5% Next Q
51
Q2 (-2Q)Grade D$0.38-2.6% Next Q
48
Q3 (-1Q)Grade D$0.37+5.4% Next Q
46
CurrentGrade D-$0.39-6.7% Hist 90D α
43
Trajectory: C- (51) → D- (43)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER
⚔️ Adversarial Opposing Case: What Could Spark a MBIO Turnaround Squeeze
While MBIO currently carries a cautious 43/100 (D-) rating due to Cash Engine Quality (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.
🚀 Contrarian Squeeze Trigger #1
Established market leader in Health Care with deep daily trading liquidity.
🚀 Contrarian Squeeze Trigger #2
Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($0.47) and Max Pain ($0.41) forces dealer call-delta covering toward $1.52.
🚀 Contrarian Squeeze Trigger #3
Forensic Repair Trigger: Halting share dilution (Disciplined Float (+0.72% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.
🎲 LIVE PREDICTION MARKET ODDS TIED TO $MBIO• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “MBIO Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
AUTOMATED RQD QUANT DESK MOVER BRIEFINGFull Market News Desk →
Why MBIO Stock surged +9.00% Today — RQD Quant Desk Flash
Mustang Bio Inc. (MBIO) surged +9.00% to $0.39, trading at 4% of its 52-week range ($0.35 – $1.45). Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.
- ▸Technical Tape: Trading at 4% of its 52-week range ($0.35 – $1.45) with RSI-14 at 44.8 (NEUTRAL RANGE).
- ▸Volatility Profile: Historical 20-day realized swing band of ±12.5% around $0.39 (no active unusual options sweep snapshot on file).
- ▸Fundamental Anchor: Roarable D- (Sell) backed by 52% gross margin and $0 annual free cash flow.
Live MBIO Headlines & Catalysts
MARKET WIRECNBC • 3h ago
Democratic Rep. Stevens endorses Rogers over El-Sayed in Michigan Senate electionHaley Stevens had lost the Democratic nomination for Senate in Michigan to Abdul El-Sayed earlier this year.
RISK WATCHReuters • 4h ago
Israeli strikes kill eight people in Gaza - medics say - ReutersIsraeli strikes kill eight people in Gaza - medics say Reuters
MARKET WIREReuters • 5h ago
Russia's FSB says minor detained over park attack threat after US tip-off - ReutersRussia's FSB says minor detained over park attack threat after US tip-off Reuters
MARKET WIREReuters • 6h ago
Iran, Qatari mediators hold third day of talks to end US-Iran war - ReutersIran, Qatari mediators hold third day of talks to end US-Iran war Reuters
CATALYSTReuters • 7h ago
Qatar surges, bucking Gulf market slide on Iran war concerns - ReutersQatar surges, bucking Gulf market slide on Iran war concerns Reuters
MARKET WIREReuters • 7h ago
OPEC+ keeps December oil output targets steady ahead of tougher call for 2027 - ReutersOPEC+ keeps December oil output targets steady ahead of tougher call for 2027 Reuters
MARKET WIREReuters • 7h ago
German ministers pledge tough action after rioters damage stores in Frankfurt - ReutersGerman ministers pledge tough action after rioters damage stores in Frankfurt Reuters
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk
Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring MBIO)
- ✓Walkthrough of MBIO's RQD Radar, SEC cash-conversion gap & downside invalidation levels
- ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
- ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
MBIO // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -47.30%▼ DESCENDING CHANNEL
2026-10-30O $0.39H $0.43L $0.39C $0.39VOL 48.3K
RES: $0.46SUP: $0.31SMA50: $0.47SMA200: $0.69
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK
MBIO Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure
Share Count & Dilution Monitor (#25)
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
Reverse-DCF Expectations Hurdle (#30)
8.0%/yr Implied 5Y Growth
vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
Ellis Vennor Setup Ledger (#33)
No active Ellis Vennor swing setup published on MBIO today. View full Setup Ledger →
🦋 Documented & Second-Order Butterfly Connections
Open Graph →
No direct multi-tier Butterfly edges indexed yet for MBIO. Explore sector supply chains on /butterfly.
AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for MBIO today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK
📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (MBIO)
Health Care Rank #565 of 1016
⚔️ CMND vs MBIO Full Matrix →
1. Head-to-Head Health Care Peer Comparison (MBIO vs. CMND, DCOY, JUNS, SXTP)
Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)Across 1016 tracked Health Care securities in the Roarable RQD universe, Mustang Bio Inc. (MBIO) ranks #565 by composite RQD confidence (43/100, grade D-) and #979 by equity capitalization ($3.0M). Within this direct 5-issuer industry benchmark cohort, MBIO leads on earnings valuation at N/A trailing P/E, while MBIO leads on capital efficiency and profitability with -35.0% ROIC and — gross margin. SXTP currently holds the highest overall quantitative score in the immediate peer group at 50/100 (D) compared with MBIO at 43/100 (D-).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| MBIO
ACTIVE
Mustang Bio Inc. | D- | 43/100 | — | — | -35.0% | +9.00% | $3.0M | Benchmark Subject |
| CMND Clearmind Medicine Inc. | D | 48/100 | — | — | — | -3.46% | $3.0M | /cmnd-vs-mbio → |
| DCOY Decoy Therapeutics Inc. | D | 45/100 | — | — | -35.0% | +11.82% | $2.9M | /dcoy-vs-mbio → |
| JUNS Jupiter Neurosciences Inc. | E | 33/100 | — | 80.6% | -35.0% | -5.20% | $3.1M | /juns-vs-mbio → |
| SXTP 60 Degrees Pharmaceuticals Inc. | D | 50/100 | — | 22.3% | -35.0% | +11.87% | $3.3M | /sxtp-vs-mbio → |
2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)
SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001680048In its most recent audited fiscal period (FY2025, filed 2025-12-31), Mustang Bio Inc. (MBIO) reported GAAP revenue of $0 (N/A vs. FY2024 revenue of $0 ) , GAAP net income of -$1.9M, operating cash flow of -$5.3M, and free cash flow of -$5.3M (+53.9% YoY). On the balance sheet, MBIO closed FY2025 with $17.6M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 2/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $0 | -$1.9M | -$5.3M | -$5.3M | $17.6M | — |
| FY2024 (FY) | 2024-12-31 | $0 | -$15.8M | -$11.4M | -$11.4M | $9.3M | — |
| FY2023 (FY) | 2023-12-31 | $0 | -$51.6M | -$49.5M | -$49.5M | — | — |
3. MBIO Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)
✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLEDIs MBIO stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
As of 2026-11-01, Mustang Bio Inc. (NASDAQ: MBIO) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 43/100 at a spot price of $0.39 (+9.00% 1D, market cap $3.0M). Pillar breakdown: Fundamental Cash Engine 4/20, Institutional 13F & Options Flow 14/20, Executive Insider Alignment 10/20, FRED Macro Regime Fit 10/20, and SEC Balance-Sheet Forensics 5/20. Across 1016 tracked Health Care issuers, MBIO ranks #565 in composite RQD confidence.
How does MBIO compare to CMND and DCOY in the Health Care sector?
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), MBIO carries a Roarable D- (43/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, CMND (Clearmind Medicine Inc.) holds a D grade (48/100 RQD, P/E N/A, ROIC —, cap $3.0M) and DCOY (Decoy Therapeutics Inc.) posts a D grade (45/100 RQD, P/E N/A, ROIC -35.0%, cap $2.9M). Among the 5-stock peer group, MBIO leads on earnings multiple (N/A) while MBIO leads on capital efficiency (-35.0% ROIC).
What are the biggest fundamental strengths and SEC risk factors for MBIO?
Per MBIO's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001680048), Mustang Bio Inc. generated $0 in revenue, -$1.9M in net income, and -$5.3M in free cash flow against $17.6M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
Where is MBIO trading relative to its 50-day, 200-day, and 52-week technical levels?
MBIO last traded at $0.39 (+9.00% on volume of 44,864 shares), positioning the stock -17.02% below its 50-day simple moving average ($0.47) and -43.48% below its 200-day simple moving average ($0.69). Across its 52-week range of $0.35 to $1.45, MBIO sits at the 3.6% percentile with a 14-day RSI of 44.8 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($1.00 to $0.44).
MBIO Investor FAQ & Complete 8-Part Research Index
100% OPEN ACCESS • SEC EDGAR × CBOE × FREDWhy is MBIO stock moving today?
Why MBIO Stock surged +9.00% Today — RQD Quant Desk Flash. Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.